Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sebastian Stintzing, Volker Heinemann, Alexander Kiani et al.|Annals of Oncology|2019

Cited by 194